title: Apoptosis inhibition mediated by medroxyprogesterone acetate treatment of breast cancer cell lines.
abstract: Several reports suggested that steroidogenic hormones could be directly involved in the regulation of apoptosis in vitro, but whether this is due to blocking or promoting mechanism of these hormones remains controversial. However, it was shown that progesterone exhibited a protective effect against the apoptotic process during mouse mammary gland involution in vivo. In this study, we analyzed the effect of medroxyprogesterone acetate (MPA) treatment, an agonist of progesterone, on serum starvation induced apoptosis on breast cancer cell lines. Positive and negative progesterone receptor (PgR+ and PgR-) breast cancer cell lines were treated with MPA (10 nM), either in standard culture conditions or in serum-free medium to induce apoptosis. Cell survival, proliferation and apoptosis were simultaneously analyzed with the expression of apoptosis-related genes measured by a real time quantitative RT-PCR. At non cytotoxic doses, MPA protected PgR+ T47-D, MCF-7 and H466-B cell lines against serum depletion-induced apoptosis, while MPA did not protect PgR-MDA-MB-231 cells against serum depletion induced apoptosis. In PgR+ cell lines and in concordance with the protective effect, the pro-apoptotic HRK and BAK1 mRNAs were up-regulated after apoptosis induction, while they were no more induced in condition of protection against apoptosis after MPA treatment. We also observed, specifically in PgR+ cells, an up-regulation of BCLX-L and BCLX-S and a down-regulation of BCL2 mRNAs, which are specific to the MPA response and unrelated to apoptotic process. Involvement of these genes with regard to the MPA-mediated protection against apoptosis is discussed.
authors.affiliation: CEA, DSV DRR, Laboratoire de Cancérologie Expérimentale, Fontenay-aux-Roses, France.
authors.forename: K
authors.initials: K
authors.lastname: Ory
authors.forename: J
authors.initials: J
authors.lastname: Lebeau
authors.forename: C
authors.initials: C
authors.lastname: Levalois
authors.forename: K
authors.initials: K
authors.lastname: Bishay
authors.forename: P
authors.initials: P
authors.lastname: Fouchet
authors.forename: I
authors.initials: I
authors.lastname: Allemand
authors.forename: A
authors.initials: A
authors.lastname: Therwath
authors.forename: S
authors.initials: S
authors.lastname: Chevillard
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects*; D017931:DNA Primers; D005260:Female; D015870:Gene Expression; D019254:Genes, bcl-2 / Q000235:genetics; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology* / Q000627:therapeutic use; D009376:Neoplasms, Hormone-Dependent / Q000517:prevention & control*; D012333:RNA, Messenger / Q000032:analysis; D011980:Receptors, Progesterone / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017931:DNA Primers; D012333:RNA, Messenger; D011980:Receptors, Progesterone; D017258:Medroxyprogesterone Acetate